12:00 AM
 | 
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Soluble Ferric Pyrophosphate: Additional Phase IIb data

Additional data from a double-blind, dose-ranging, North American Phase IIb trial in 131 dialysis patients showed that 10 µg/dL SFP met the secondary endpoint of significantly increasing hemoglobin from baseline vs. placebo after a mean treatment duration of 13.4 weeks (p=0.049). The 5, 12 and 15 µg/dL doses of SFP missed the endpoint (p=0.234, 0.375...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >